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PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF
The present invention relates to dipeptide or pseudodipeptide derivatives 
containing an aminoalkanoyl group disubstituted on at least one of the carbon atoms of 
the chain, with metabolic quenching activity towards carbonyl compounds.
Prior art
5 The influence of oxidative damage on triggering various physiopathological
processes, including aging, inflammatory disorders, diabetes, cardiovascular disease and 
neurodegenerative processes, has long been recognised. The main molecular mechanisms 
responsible for oxidative damage, such as structural damage to proteins, lipids and 
nucleic acids caused by radical reactive oxygen species, and an altered cell redox state, 
10 are also well known [Halliwell B, Gutteridge JM. Free Radicals in Biology and Medicine 
(2001) Oxford Science Publications, 3rd Ed.].
It has also been clarified that some products of lipid oxidation characterised by a 
keto/aldehyde function act as important cytotoxic oxidative mediators, inducing 
irreversible structural modifications of the biomolecules, leading to alteration of the cell 
15 functions [Uchida K. Free Radic. Biol. Med. 2000; 28:1685-96.; Poli G. et al., IUBMB 
Life. 2000; 50:315-21],
The carbonyl compounds studied include the products of oxidation of 
polyunsaturated fatty acids, including alpha, beta-unsaturated aldehydes such as 
4-hydroxy-trans-2-nonenal (HNE) and acrolein (ACR) [Esterbauer H. et al., Free Radic. 
20 Biol. Med. 1991; 11:81-128],
The participation of unsaturated aldehydes in various pathological processes with 
an oxidative basis has been demonstrated with the use of mono- and polyclonal antibodies 
[Uchida K. Prog. Lipid Res. 2003; 42:318-43], In particular, adducts between HNE and 
acrolein with proteins have been identified in biopsy and autopsy tissue of patients 
25 suffering from diabetes, atherosclerosis, muscular dystrophy, rheumatoid arthritis, actinic 
elastosis, cerebral ischaemia and neurodegenerative diseases such as Alzheimer’s disease
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and Parkinson’s disease [Uchida K. Prog. Lipid Res. 2003; 42:318-43.; Zarkovic N. Mol. 
Aspects Med. 2003; 24:281-91.; Zarkovic N. Mol. Aspects Med. 2003; 24:293-303.; 
M. Carini et al. in “Redox Proteomics: from Protein Modifications to Cellular 
Dysftmction and Diseases” (Ed. I. Dalle-Donne5 A. Scaloni5 and A. Butterfield); Wiley 
5 InterScience Books from John Wiley & Sons (2005)].
The role of HNE as a pathogenetic factor has been demonstrated at molecular 
level for various disorders such as fibrosis [Chiarpotto E. et al., Biofactors. 2005; 
24(1-4):229-36], diabetic nephropathy [Furfaro AL. et al. Biofactors. 2005;24(l-4): 
291-8.], atherosclerotic processes [Leonarduzzi G. et al., Mol Nutr Food Res. 2005 
10 Nov;49(l 1):1044-9] and neurodegenerative disorders [Zarkovic K. Mol Aspects Med. 
2003 Aug-Oct;24(4-5) :293-303].
It is therefore evident that carbonyl products, especially reactive carbonyl 
compounds such as HNE, are important targets for the development of a new class of 
biologically active molecules with carbonyl-quenching activity.
15 This interest is clearly demonstrated by the considerable number of articles and
patents describing compounds with carbonyl-quenching activity, especially dipeptide 
compounds correlatable with camosine [Hipkisss A.R., J. Alzheimer’s Dis. 2007, 77, 
229-240; Guiotto A. et al. Curr. Med. Chem. 2005, 12,2293-2315 ; Vistoli G. et al., 
Chem. Med. Chem. 2009,4 (6), 967-975].
20 Peptide compounds which are structurally correlatable with camosine and their
carbonyl-quenching activity are also described, for example, in W02008/001174, while 
some aminoalcohol derivatives are described in WO2011/080139.
Description of the invention
The present invention relates to peptide or pseudopeptide derivatives containing a 
25 nitrogenous heterocyclic residue which have demonstrated an interesting activity of 
blocking the by-products of oxidative lipid stress, in particular those of unsaturated 
aldehydes such as malondialdehyde and 4-hydroxy-trans-2-nonenal (HNE), which are 
known for their contribution to the onset of a considerable number of chronic disorders
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such as neurodegenerative disorders, chronic inflammatory disorders, cardiovascular 
disease, and complications of diabetes and cataract. This novel series of compounds, 
studied as from the structure of the endogenous L-camosine dipeptide present in some 
tissues of the human body, is characterised by the presence of a double substitution on 
5 one of the carbons of the beta-alanine chain and the presence of a hydroxymethyl group
optionally substituted for the terminal carboxyl group of L-camosine. The compounds 
have demonstrated a surprisingly greater activity of the dipeptide L-camosine and the 
corresponding aminoalcohols in quenching model carbonyl compounds, and extremely 
high metabolic stability compared with that of L-camosine or structurally correlated 
10 compounds. These characteristics make them suitable for therapeutic use in all disorders 
correlatable with the presence of reactive carbonyl compounds.
The invention also relates to said compounds for use in the treatment or 
prevention of said disorders.
The compounds forming the object of the invention have the general formula I
15
I
wherein:
Ri is a 5-6 membered heterocyclic ring optionally fused to a benzene ring, 
20 containing one to three nitrogen atoms optionally bearing C1-C3 alkyl substituents;
R2 is:
- a CH2-O-R group wherein R represents hydrogen, a straight or branched C1-C10 
alkyl group or a C3-C8 cycloalkyl group, a straight or branched Ci-Cs alkylcarbonyl 
group, a C3-C8 cycloalkylcarbonyl group; or R is an Ar(CH2)PC(=0)- group wherein Ar is 
25 an aryl selected from phenyl and naphthyl optionally substituted with one or two groups
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selected from the group of methyl, methoxy or ethyl, and p is zero or an integer between 1 
and 3;
- a COORe group wherein Rs represents hydrogen, a straight or branched Ci-Cio 
alkyl group or a C3-C8 cycloalkyl group;
Rj is a group of general formula II
D
(CH2)n (CH2)q
wherein
n and q, independently of one another, are equal to zero or represent an integer 
between 1 and 4;
R6 and R7, which are the same or different, represent:
- hydrogen;
- a straight or branched C1-C20 alkylcarbonyl group or a C3-C7 cycloalkylcarbonyl 
group optionally containing one or more double bonds, or an Ar(CH2)PC(=0)- group 
wherein Ar and n are as defined above;
- a straight or branched C1-C10 alkoxycarbonyl group or a C3-C7 
cycloalkoxycarbonyl group optionally containing one or more double bonds, or an 
Ar0(CH2)nC(=0)- group wherein Ar and n are as defined above;
- one of R6 and R7 is an amino group and the other is hydrogen;
- one of R6 and R7 is hydrogen and the other is a group of formula III
H
III
wherein M represents nitrogen, oxygen or sulphur and A represents hydrogen or 
an amino group, and the free valence of the carbon atom forms a bond with the nitrogen
WO 2019/130164 PCT/IB2018/060332
atom of the group of formula II;
R4 and R 5, which are the same or different, represent:
- a straight or branched Ci-Cs alkyl group, preferably methyl;
- a halogen, preferably fluorine;
- can be joined to form, together with the carbon atom to which they are linked, a 
cycloaliphatic ring with 3 to 6 carbon atoms selected from cyclopropyl, cyclobutyl, 
cyclopentyl and cyclohexyl forming an R3 group of general formula IV
5
Re
\
N.
'(CH2)n (CH2)q
IV
wherein
m has a value ranging between 1 and 4;
R6, R7, n and q have the meanings described above.
In general formula I, wavy bond indicates that the carbon atom
substituted with NH and R2 can have the R or S configuration.
In general formulas II and IV, the free valence of the carbon atom of the carbonyl 
group forms a bond with the nitrogen atom of formula I.
Examples of a 5-6 member heterocyclic ring comprise imidazole, pyrrole, 
pyrazole, triazole, indole, isoindole, indazole, benzoimidazole and benzotriazole.
In one embodiment of the invention:
Ri is a heterocyclic ring selected from imidazole, pyrrole, pyrazole, triazole, 
indole, isoindole, indazole, benzoimidazole and benzotriazole, preferably imidazole or 
imidazole substituted at the nitrogen atom at the 1- position or at the 3- position with 
methyl, ethyl or propyl;
Rz and R3 are as defined above.
In another embodiment of the invention:
510
15
20
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Ri is imidazole optionally substituted at the nitrogen atom at the 1- position or at 
the 3- position with methyl, ethyl or propyl;
R2 is Cth-OH or a COORs group wherein Rs is selected from hydrogen, methyl 
and ethyl.
R3 is a group of formula II wherein R4 and Rs are both methyl or halogen, R6 and 
R7 are both hydrogen, or one of R6 and R7 is hydrogen and the other is a straight or 
branched C1-C10 alkoxycarbonyl group or a C3-C7 cyclic group, and π and q are as 
defined above.
In another embodiment of the invention:
Ri is imidazole optionally substituted at the nitrogen atom at the 1- position or at 
the 3- position with methyl, ethyl or propyl;
R2 is CH2-OH or a COORs group wherein Rs is selected from hydrogen, methyl 
and ethyl;
R3 is a group of formula IV wherein R4 and Rs are joined to form, together with 
the carbon atom to which they are bonded, a cycloaliphatic ring with 3 to 6 carbon atoms 
selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, R6 and R7 are both 
hydrogen, or one of R6 and R7 is hydrogen and the other is a straight or branched C1-C10 
alkoxycarbonyl group or a C3-C7 cyclic group, and m, n and q are as defined above.
In a preferred embodiment:
Ri is imidazole optionally substituted at the nitrogen atom at the 1- position or at 
the 3- position with methyl;
R2 is CH2-OH or a COORs group wherein Rs is hydrogen;
R3 is a group of formula II wherein R4 and Rs are both methyl or fluorine, R6 and 
R7 are both hydrogen, and n and q are as defined above.
In another preferred embodiment:
Ri is imidazole optionally substituted at the nitrogen atom at the 1- position or at 
the 3- position with methyl;
R2 is CH2-OH or a COORs group wherein Rs is hydrogen.
6
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R3 is a group of formula IV wherein R.4 and Rs are joined to form, together with 
the carbon atom to which they are bonded, a cycloaliphatic ring with 3 to 6 carbon atoms 
selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, R6 and R7 are both 
hydrogen, and m, n and q are as defined above.
Examples of compounds according to the invention are:
(S)-2-amino-N-(l-hydroxy-3-(lH-imidazol-4-yl)propan-2-yl)-2-
methylpropanamide;
(S)-3 -amino-N-( 1 -hydroxy-3 -(1 H-imidazol-4-yl)propan-2-yl)-2,2- 
dimethylpropanamide;
(S)-4-amino-N-( 1 -hydroxy-3 -(1 H-imidazol-4-yl)propan-2-yl)-2,2- 
dimethylbutanamide;
(S)-1 -(aminomethyl-N-( 1 -hydroxy-3 -(1 H-imidazol-4-yl)propan-2-yl) 
cyclopropanecarboxamide;
(S)-1 -(aminomethyl-N-(l -hydroxy-3-(l H-imidazol-4-yl)propan-2-yl) 
cyclobutanecarboxamide;
(S)-I -(aminomethyl-N-( 1 -hydroxy-3 -(1 H-imidazol-4-yl)propan-2-yl) 
cyclopentanecarboxamide;
(S)-I -(aminomethyl-N-(1 -hydroxy-3 -(1 H-imidazol-4-yl)propan-2-y 1) 
cyclohexanecarboxamide;
(S)-3 -amino-N-( 1 -hydroxy-3 -(1 -methyl-1 H-imidazol-5-yl)propan-2-yl)-2,2- 
dimethylpropanamide;
(S)-3-amino-N-(l-hydroxy-3-(lH-imidazol-4-yl)propan-2-yl)-3,3-
dimethylpropanamide;
(S)-3-amino-2,2-difluoro-N-(l-hydroxy-3-(lH-imidazol-4-yl)propan-2-yl)-
propanamide;
N-(2-amino-2-methylpropanoyl)-L-histidine;
N-(3-amino-2,2-dimethylpropanoyl)-L-histidine
N-(l -aminomethyl)-1 -cyclopropylcarbonyl)-L-histidine;
7
510
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N-(l -axninomethyl)-l -cyclobutylcarbonyl)-L-histidine;
N-(l -aminomethyl)-1 -cyclopentylcarbonyl)-L-histidine
N-( 1 -aminomethyl)-1 -cy clohexylcarbonyl)-L-histidine;
N-(4-amino-2,2-dimethylbutanoyl)-L-histidine;
N-(3 -amino-3,3 -dimethy lpropanoy l)-L-histidine;
N-(3-amino-2,2-dimethylpropanoyl)-L-histidine
N-(3-amino-2,2-difluoropropanoyl)-L-histidine.
As at least one chiral centre is present in the compounds of formula I, all the 
optical isomers of the products in question and the mixtures thereof in any proportion, and 
all the possible diastereoisomers, taken individually or mixed together in any proportion, 
are deemed to constitute an integral part of the invention. All the pharmacologically 
acceptable salts of the products of formula I are also part of the invention.
The compounds according to the invention were synthesised by some of the 
well-known solid-phase or solution-phase peptide synthesis methods reported in the 
literature, for example in Houben-Weil “Synthesis of peptides and peptidomimetics” vol. 
E22 a-d or J. Jones “Amino acid and peptide synthesis”. The amino acids used in the 
synthesis, if not available in an already protected form, were suitably functionalised with 
the necessary protecting groups using well-known methods, such as those reported in 
T.W. Greene, P.G.M. Wuts “Protective group in organic synthesis” or P.J. Kocienski 
“Protecting groups”. The aminoalcohols used in the synthesis were prepared by reduction 
of derivatives of the corresponding amino acids using suitable metal or organometal 
hydrides in inert solvents, and similar procedures were used in the reduction of dipeptide 
to ammoacylaminoalcohol derivatives.
The end products obtained were purified, when necessary, by one of the methods 
known to the skilled person, using, for example, crystallisation, chromatographic 
purification or any other technique required to obtain compounds with the required degree 
of purity.
By way of example, the compounds according to the invention can be prepared
8
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according to synthesis scheme 1. A suitable aminoester of formula VI wherein R is a 
C1-C3 alkyl is coupled with the corresponding protected amino acid of formula VII 
wherein R4, Rs3 n and q are as defined above, and R’6 is a protecting group of the nitrogen 
atom according to one of the known methods, and the resulting protected dipeptide ester 
of formula VIII can subsequently be reduced to the corresponding alcohol EX and 
deprotected to obtain the corresponding aminoalcohol X. Alternatively, the protected 
dipeptide ester of formula VIII can be hydrolysed and deprotected to obtain the peptides 
of formula XI.
Sy
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The pharmacological activity of the compounds according to the invention was 
determined in vitro by evaluating their carbonyl-quenching activity towards 4-hydroxy 
nonenal (HNE), which is known for its involvement in numerous disorders. Said activity was 
compared with that of L-camosine, a compound known as a carbonyl quencher in vitro but 
5 having limited metabolic stability caused by serum camosinase. The metabolic stability of a 
particularly interesting compound was also evaluated in human serum after 1 and 2 hours.
The results of the pharmacological tests clearly demonstrate that some of the 
compounds according to the invention possess carbonyl-quenching activity which is 
considerably greater than that of L-camosine and significantly greater than that of other 
10 compounds that do not bear substituents on the alkyl chain, which are described above. For 
this purpose it is interesting to compare the compound 2-amino-V-(l -hydroxy-3-(U/- 
imidazoI-4-yl)propan-2-yl)-2-methyIpropanamide (FLM-04-OLO) forming the object of 
the present invention, which exhibits carbonyl-quenching activity 3.1 times greater than that 
of L-camosine (see Table I), with that of the non-disubstituted derivative 3-amino-vV-[(l S)- 
15 2-hydroxy-l-(lH-imidazol-5-yl-methyl)ethyl]propanamide reported in WO2011/080139,
an activity whereof, 1.6 times greater than that of L-camosine, is reported in the same test.
For the intended uses, the compounds of formula I are conveniently formulated in 
conventional pharmaceutical, cosmetic or nutritional compositions suitable for oral, 
parenteral, topical or transdermal administration, which constitute a further object of the 
20 invention. Examples of said compositions include capsules, tablets, syrups, injectable 
solutions or suspensions, ointments, suppositories, controlled-release forms and the like, 
and water-soluble granulates. Said forms, plus carriers and excipients used in 
pharmaceutical technology, could optionally also contain other active ingredients which 
have a complementary activity or are otherwise useful for the treatment/prevention of the 
25 disorders in question. The invention is illustrated in detail in the following examples.
General example of procedure 1
In an anhydrous medium, under argon, the acid of structure VII (1 equiv.) is 
dissolved in anhydrous CH3CN (5 mL/mmol), and the mixture is cooled to 0°C. HATU
11
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(1.05 equiv.) is added, and DlPEA (2 equiv.) is dripped in. The reaction mixture is left 
under magnetic stirring at O0C for 5 min, and a solution of compound VI (1 equiv.) and 
DIPEA (2 equiv.) in anhydrous CH3CN (5 mL/mmol) is then dripped in. The resulting 
mixture is left under stirring at room temperature for 2-4 hours. At the end of the reaction 
5 (TLC assay [DCM/MeOH 7:3]) the solvent is evaporated under low pressure. The residue 
is taken up with EtOAC and washed with a Na2C03 saturated solution and a NH4CI 
saturated solution. The organic phase is dried with anhydrous Na2S04, filtered and 
concentrated under low pressure. The crude product is optionally purified by column 
chromatography on silica gel, to obtain the compounds of general structural formula VIII.
10 General example of procedure 2
The compound of structure VIII (1 equiv.) is dissolved in THF and MeOH (1:1) (8 
mL/mmol), and the mixture is cooled to 0°C with an ice bath. NaBH4 (10 equiv.) is added 
slowly under magnetic stirring. The reaction mixture is left under stirring at 0°C for 2 h. 
The disappearance of the starting compound is tested for by TLC (EtOAc/MeOH 85:15), 
15 and the solvent is evaporated under low pressure at the end of the reaction. The crude 
product is taken up with EtOAc and washed with a NH4CI saturated solution. The organic 
phase dried with anhydrous Na2S04 is filtered and concentrated under low pressure, and 
the resulting residue is purified by column chromatography on silica gel to obtain the 
compounds of general structure IX.
20 General example of procedure 3
Trifluoroacetic acid (10 equiv.) is slowly dripped into a solution of the N- 
protected aminoalcohol of structure IX in dichloromethane (10 mL/mmol), precooled to 
O0C, under magnetic stirring. The reaction mixture is left under stirring at room 
temperature for 1.5 h. When the reaction is complete (TLC assay [EtOAc/MeOH 8:2]), 
25 the solvent is removed under low pressure. The residue is diluted in 2N HCl and loaded 
into a Dowex50WX2® ion-exchange resin column. The purification is carried out by 
washing with deionised water and eluting the aminoalcohol of structure X with a 10% 
aqueous solution of NH3.
12
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General example of procedure 4
A solution of intermediate VIII in DCM (10 mL/mmol) is cooled to 0°C with an 
ice bath. TFA (10 equiv.) is dripped in, and the resulting mixture is left under stirring at 
room temperature for 2 h. On the disappearance of the starting product (TLC assay 
5 [EtOAc/MeOH 8:2]), the solvent and the excess TFA are removed under low pressure. 
The residue is dissolved in THF and the mixture is cooled to 0°C. An aqueous solution of 
2N LiOH is slowly dripped in under magnetic stirring until a basic pH is reached, and the 
reaction mixture is left under stirring at room temperature until the reaction is complete 
(TLC assay [EtOAc/MeOH/hfflb 10% aqueous solution]). The reaction mixture is 
10 concentrated under low pressure, acidified with 2N HCl and loaded into a 
Dowex50WX2® ion-exchange resin column. After washing with deionised water, 
compound XI is released from the resin with a 10% aqueous solution of NH3.
The following compounds were obtained with the general procedure described above.
Example 1: (iS)-2-amino-IV-(l-hy droxy-3-(LSr-imidazoI-4-yl)propan-2-yl)-2- 
15 methylpropanamide (code FLM-05 OLO)
(S)-methyl-2-(2-((tert-butoxycarbonyl)amino)-2-methylpropanamido)-3-(lH- 
imidazol-4-yl)propanoate (Procedure 1)
1H NMR (300 MHz, CDC13) 5 7.52 (s, 1H), 6.76 (s, 1H), 5.24 (br s, 1H), 4.70 
(dd, J = 11.2, 4.8 Hz, 1H), 3.70 (s, 3H), 3.33 - 3.18 (m, 1H), 3.11 (dd, J = 15.0, 5.2 Hz, 
20 1 H), 1.49 (s, 6H), 1.42 (s, 9H).
(S)-tert-butyl( 1-((1 -hydroxy-3 -(1 H-imidazol-4-yl)propan-2-yl)amino)-2-methyl-1 - 
oxopropan-2-yl)carbamate (Procedure 2 Yield 46%).
1H NMR (300 MHz, CD30D) δ 7.61 (s, 1H), 6.87 (s, 1H), 4.20 - 4.00 (m, 1H), 
3.58 - 3.45 (m, 2H), 2.88 (dd, J = 14.9, 6.0 Hz, 1H), 2.77 (dd, J - 14.9, 7.9 Hz, 1H), 1.42 
25 (s,9H), 1.36 (s,3H), 1.32 (s,3H).
(S)-2-amino-N-(l-hydroxy-3-(lH-imidazol-4-yl)propan-2-yl)-2- 
methylpropanamide (Procedure 3. Yield 79%.)
13
1H NMR (300 MHz, CD30D) δ 7.57 (s, 1H), 6.85 (s, 1H), 4.15 - 3.99 (m, 1H),
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Example 2: (iS)-3-ammo-7V-(l-hydroxy-3-(lHr-imidazol-4-y!)propan-2-yI)-2,2- 
dimethylpropanamide (code FLM 04 OLO)
5 r5,)-methyl-2-n-i(/gr/-butoxvcarbonyl)amino)-2.2-dimethvlpropanamido')-3-(l/7-
imidazol-4-yl)propanoate (procedure 1)
1H NMR (300 MHz5 CDCl3) δ 7.59 (s, 1H), 7.54 (br s, 1H), 6.80 (s, 1H), 5.68 (br 
s, 1H), 4.74 (dd, J= 11.9, 4.9 Hz5 1H), 3.70 (s, 3H), 3.35 - 3.03 (m, 4H), 1.42 (s, 9H), 
1.22 (s, 3H), 1.20 (s, 3H).
10 (S)-fe7t-butyl(3 -((1 -hydroxy-3 -f 1 iJ-imidazol-4-vDpropan-2-yl)amino)-2,2-
dimethvl-3-oxopropyl) carbamate (Procedure 2, yield 80%).
1H NMR (300 MHz5 CD3OD) δ 7.61 (s, 1H), 6.86 (s, 1H), 4.19 - 4.10 (m, 1H),
3.55 (d, J= 5.5 Hz5 2H), 3.23 - 3.06 (m, 2H), 2.88 (dd, J= 14.9, 5.9 Hz5 1H), 2.77 (dd, J 
= 14.9, 8.2 Hz5 1H), 1.43 (s, 9H), 1.10 (s, 3H), 1.07 (s, 3H).
15 (S)-3-amino-iV-fl -hydroxy-3 -Π 77-imidazol-4-yl)propan-2-vl)-252-
dimethylpropanamide (Procedure 3, yield 92%).
1H NMR (300 MHz5 CD3OD) δ 7.56 (s, 1H), 6.84 (s, 1H), 4.22 - 4.12 (m, 1H),
3.55 (d, J= 5.5 Hz5 2H), 2.88 (dd, J= 14.8, 5.7 Hz5 1H), 2.77 (dd, J= 14.8, 8.4 Hz5 1H), 
2.65 (s, 2H), 1.11 (s, 3H), 1.09 (s, 3H).
20 Example 3: (N)-4-amino-Ar-(l-hydroxy-3-(17/-imidazol-4-yI)propan-2-yl)-2,2-
dimethylbutanamide (code FLM 13 OLO)
OSVmethyl 2-f4-('/g7y-butoxycarbonylamino)-2.2-dimethylbutanamido)-3-n7/-
imidazo1-4-yl)propanoate (procedure 1)
1H NMR (300 MHz5 acetone) δ 7.99 (d, J= 6.4 Hz5 1H), 7.70 (s, 1H), 6.98 (s, 
25 1H), 6.05 (br s, 1H), 4.71 - 4.65 (m, 1H), 3.62 (s, 3H), 3.20 - 2.86 (m, 4H), 1.72 (dd,
J= 9.1, 5.6 Hz5 2H), 1.39 (s, 9H), 1.18 (s, 6H).
14
3.55 (d, J = 5.1 Hz5 2H), 2.89 (dd, J = 14.8, 6.0 Hz5 1H), 2.78 (dd, J = 14.8, 8.0 Hz5 1H),
1.26 (s, 3H), 1.23 (s, 3H).
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(M-/gr/-butyl 4-( 1 -hydroxy-3 -(1 77-imidazol-4-yl)propan-2-ylamino)-3,3 ■-dimethyl-
4-oxobutylcarbamate (procedure 2, yield 68%)
1H NMR (300 MHz, CD3OD) δ 7.73 (s, 1H), 6.91 (s, 1H), 4.27 - 4.07 (m, 1H), 
3.63 - 3.49 (m, 2H), 2.96 - 2.86 (m, 3H), 2.81 (dd, J= 14.9, 8.6 Hz, 1H), 1.69 - 1.61 (m, 
2H), 1.42 (s, 9H), 1.12 (s, 3H), 1.11 (s, 3H).
(,SV4-ammo-.iV-( 1 -hydroxy-3-C 177-imidazol-4-yl)propan-2-yl')-2,2- 
dimethylbutanamide (67 mg, 0.27 mmol) (procedure 3, yield 83%.
1H NMR (300 MHz, D2O) δ 7.66 (s, 1H), 6.92 (s, 1H), 4.33 - 4.18 (m, 1H), 
3.71 - 3.56 (m, 2H), 2.89 (dd, J= 14.9, 4.7 Hz, 1H), 2.79 - 2.67 (m, 1H), 2.45 - 2.27 (m, 
2H), 1.69 - 1.50 (m, 2H), 1.09 (s, 3H), 1.07 (s, 3H).
Example 4: (1S)-l-(aminomethyl)-7V-(l-hydroxy-3-(lJHr-imidazoI-4-yl)propan-
2- yl)cycloproparaecarboxamide (code FLM-9 OLO)
OSymethyl 2-( 1 -(((/er/-butoxycarbonvl)amino)methyDcyclopropanecarboxamido)-
3- (17f-imidazol-4-vl)propanoate (procedure 1)
1H NMR (300 MHz, acetone-de) δ 8.08 (br s, 1H), 7.64 (s, 1H), 6.99 (s, 1H), 6.68 
(br s, 1H), 4.59 (dd, J= 12.7, 6.8 Hz, 1H), 3.61 (s, 3H), 3.44 (dd, J= 15.0, 7.0 Hz, 1H), 
3.29 (dd, J= 15.0, 5.5 Hz, 1H), 3.07 - 2.95 (m, 2H), 1.43 (s, 9H), 1.10 - 0.99 (m, 2H), 
0.85 - 0.75 (m, 2H).
(S)-/er/-butyl_________________ ((1-((1 -hydroxy-3-( l/7-imidazol-4-yr)propan-2-
vPcarbamoyDcyclopropvDmethyl) carbamate (procedure 2, yield 93%).
1H NMR (300 MHz, CD3OD) δ 7.61 (s, 1H), 6.87 (s, 1H), 4.17 - 4.08 (m, 1H), 
3.53 (d, J= 5.4 Hz, 2H), 3.27 (s, 2H), 2.90 (dd, J= 14.8, 6.0 Hz, 1H), 2.75 (dd, J= 14.8, 
8.1 Hz, 1H), 1.44 (s, 9H), 1.09 - 1.01 (m, 2H), 0.75 - 0.72 (m, 2H).
(,SrI-I -(aminomethvl)-jV-(l-hvdroxy-3-(177-imidazol-4-yl)propan-2- 
vl)cyclopropanecarboxamide (procedure 3, yield 86%).
1H NMR (300 MHz, CD3OD) δ 7.57 (s, 1H), 6.84 (s, 1H), 4.19 - 4.08 (m, 1H),
3.55 (d, J= 5.3 Hz, 2H), 2.92-2.71 (m, 4H), 1.09 - 0.97 (m, 2H), 0.74 - 0.63 (m, 2H).
Example 5: (S)-l-(ammomeihyi)-AL(l-hydroxy-3-(LfiT-imidazo]!-4-yl)propan-
15
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2-yI)cyclobutanecarboxamide (code FLM-IO OLO)
(■SVmethyl 2-( 1 -(((/e/y-butoxvcarbonvDaminolmethvDcyclobutanecarboxamidoV
1 3-(17/-imidazol-4-vl)propanoate (procedure 1)
1H NMR (300 MHz, CD3OD) δ 7.61 (s, 1H), 6.89 (s, 1H), 4.67 (dd, J= 8.3, 5.3 Hz, 
5 1H), 3.71 (s, 3H), 3.48 - 3.33 (m, 2H), 3.16 (dd, J= 14.8, 5.2 Hz, 1H), 3.06 (dd, J= 14.8,
8.4 Hz, 1H), 2.32-2.13 (m, 2H), 2.04-1.85 (m, 3H), 1.84-1.67 (m, 1H), 1.43 (s, 9H).
(TTHerf-butyl_______________((1-((1 -hydroxy-3-(1 //-imidazol-4-yl)propan-2-vl)
carbamoyl)cyclobutyl)methyl) carbamate (procedure 2, yield 73%).
1H NMR (300 MHz, CD3OD) δ 7.60 (s, 1H), 6.87 (s, 1H), 4.20 - 4.12 (m, 1H), 3.61 
10 - 3.51 (m, 2H), 3.45 - 3.31 (m, 2H), 2.87 (dd, J= 14.8, 6.0 Hz, 1H), 2.78 (dd, J= 14.8, 8.2
Hz, 1H), 2.31 -2.09 (m, 2H), 2.01 - 1.80 (m, 3H), 1.80-1.60 (m, 1H), 1.41 (s, 9H).
(Sf)-l-(ammomethyl)-Ar-( 1 -hydroxy-3-(177-imidazol-4-yl)propan-2- 
vDcyclobutanecarboxamide (procedure 3, yield 96%).
1H NMR (300 MHz, CD3OD) δ 7.57 (s, 1H), 6.86 (s, .1H), 4.26 - 4.13 (m, 1H), 
15 3.66 - 3.48 (m, 2H), 2.97 - 2.83 (m, 3H), 2.76 (dd, J= 14.8, 8.7 Hz, 1H), 2.37 - 2.17 (m,
2H), 2.00-1.67 (m,4H).
Example 6: (5)-l-(aminomethyl)-Ar-(l-hydroxy-3-(lJr-imidazol-4-yl)propan- 
2-yl)cyclopentanecarboxamide (code FLM-11 OLO)
(iSVmethyl 2-(l-(((/er/-butoxvcarbonyI)amino)methvl)cvclopentanecarboxamidoV 
20 3-(li7-imidazol-4-yl)propanoate (procedure 1)
1H NMR (300 MHz, CD3OD) δ 7.59 (s, 1H), 6.87 (s, 1H), 4.64 (dd, J= 8.3, 5.3 
Hz, 1H), 3.71 (s, 3H), 3.24 (d, J= 6.1 Hz, 2H), 3.15 (dd, J= 14.7, 5.1 Hz, 1H), 3.06 (dd, 
J= 14.8, 8.4 Hz, 1H), 1.97- 1.78 (m, 2H), 1.73-1.51 (m, 6H), 1.43 (s, 9H).
(JV/erf-butyl_________________ ((1 -((1 -hydroxy-3-( 1 H-imidazol-4-yl)propan-2-
25 vl)carbamoyOcvclopentvl)methvl) carbamate (procedure 2, yield 92%).
1H NMR (300 MHz, acetone-d6) δ 7.69 (s, IH), 7.17 (d, J= 7.4 Hz, 1H), 6.94 (s, 
1H), 6.44 (br s, 1H), '6.06 (br s, 2H), 4.16 - 4.03 (m, IH), 3.58 - 3.41 (m, 2H), 3.31 (dd, J 
= 13.8, 6.7 Hz, IH), 3.22 (dd, J= 13.7, 6.1 Hz, IH), 2.93 -2.78 (m, 2H), 2.02 - 1.82 (m,
16
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2H), 1.71-1.50 (m, 6H), 1.40 (s, 9H).
OSV1 -(anunomethylVAV 1 -hydroxy-3-( 177-iniidazol-4-vl)propan-2- 
vLcvclopentanecarboxamide (procedure 3, yield 78%).
1H NMR (300 MHz, CD3OD) δ 7.56 (s, IH), 6.84 (s, 1H), 4.25 - 4.14 (m, 1H),
3.62 - 3.49 (m, 2H), 2.88 (dd, J= 14.8, 5.6 Hz, 1H), 2.77 (dd, J= 14.9, 8.7 Hz, 1H), 2.71 
(s, 2H), 2.03 - 1.86 (m, 2H), 1.68 - 1.44 (m, 6H).
Example 7: (5)-l-(aminomethyl)-7V-(l-iiydroxy-3-(Lfir-imidazol-4-yI)propan- 
2-yl)cydofaexanecarboxamide (code FLM-14 OLO)
QSVmethyl 2-( 1 -f(fer/-butoxycarbonylamino)methvl)cyclohexanecarboxamidoV3-
(1 /jr-imidazol-4-yI)propanoate (procedure 3)
1H NMR (300 MHz, CD3OD) δ 7.62 (s, 1H), 6.89 (s, 1H), 4.69 (dd, J= 8.5, 5.2 
Hz, 1H), 3.73 (s, 3H), 3.23 - 3.04 (m, 4H), 2.03 - 1.89 (m, 2H), 1.61 - 1.48 (m, 3H), 1.43 
(s, 9H), 1.37-1.16 (m, 5H).
OSVfer/-butyl______ (1 -(1 -hydroxy-3 -(1 /7-imidazol-4-vl)propan-2-ylcarbamoylV
cyclohexvDmethyl carbamate (procedure 2, yield 88%).
1H NMR (300 MHz, CD3OD) <5 7.59 (s, 1H), 6.87 (s, 1H), 4.28 - 4.15 (m, 1H),
3.63 - 3.50 (m, 2H), 3.23 - 3.12 (m, 1H), 3.10 - 2.99 (m, 1H), 2.93 - 2.74 (m, 2H), 2.03 
- 1.86 (m, 2H), 1.59 - 1.46 (m, 3H), 1.42 (s, 9H), 1.36 - 1.08 (m, 5H).
OSVl -(aminomethvl VjV-n-hvdroxy-3-(177-imidazol-4-vl)propan-2-yl)cvclo-
hexanecarboxamide (procedure 3, yield 92%).
1H NMR (300 MHz, CD3OD) δ 7.56 (s, 1H), 6.86 (s, 1H), 4.36 - 4.19 (m, 1H), 
3.65 - 3.50 (m, 2H), 2.88 (dd, J= 14.9, 5.4 Hz, 1H), 2.78 (dd, J= 14.9, 9.0 Hz, 1H), 2.58 
(s, 2H), 2.06-1.94 (m, 2H), 1.60 - 1.44 (m, 3H), 1.36 - 1.11 (m, 5H).
Example 8: (.S)-3-ammo-7V-(l-faydroxy-3-(l-methyl-li/-imidazol-5-yl)propan- 
2-yl)-2,2-dimethylpropanamide (FLM-12 OLO)
(.SfI-Inethvl 2-(3-((ie?7-butoxvcarbonyl)amipo)-2.2-dimethylpropanamido)-3-( 1 -
17
methyl- 17f-imidazol-5-yl)propanoate (procedure 1)
1H NMR (300 MHz, CD3OD) δ 7.54 (s, 1H), 6.75 (s, 1H), 4.68 (dd, J= 9.7, 5.4
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Hz, 1H), 3.74 (s, 3H), 3.66 (s, 3H), 3.23 (dd, J= 15.5, 5.4 Hz, 1H), 3.15 (s, 2H), 3.08 (dd, 
J- 15.5, 9.8 Hz, 1H), 1.43 (s, 9H), 1.11 (s, 3H), 1.08 (s, 3H).
(S)-tert- butyl (3-(( 1 -hydroxy-3-f 1 -methvl-17i/-imidazol-5-yl)propan-2-vl)aniino)-
2.2-dimethvl-3-oxopropyI)carbamate (procedure 2, yield 91%).
5 1H NMR (300 MHz, CD3OD) δ 7.55 (s, 1H), 6.75 (s, 1H), 4.22 - 4.10 (m, 1H),
3.69 (s, 3H), 3.58 (d, J= 5.4 Hz, 2H), 3.21 - 3.05 (m, 2H), 2.91 (dd, J= 15.4, 5.7 Hz, 
1H), 2.75 (dd, J= 15.3, 9.2 Hz, 1H), 1.43 (s, 9H), 1.09 (s, 3H), 1.05 (s, 3H).
(5)-3-amino-jVJ 1 -hvdroxy-3 -(1 -methyl-1 /7-imidazol-5-yl)propan-2-yl)-2.2-
diro ethyl propanamide ( procedure 3, yield 73%).
10 1H NMR (300 MHz, CD3OD) S 7.51 (s, 1H), 6.74 (s, 1H), 4.25 - 4.15 (m, 1H),
3.68 (s, 3H), 3.59 (d, J= 5.4 Hz, 2H), 2.90 (dd, J= 15.3, 5.6 Hz, 1H), 2.76 (dd, J= 15.3, 
9.4 Hz, 1H), 2.64 (s, 2H), 1.11 (s, 3H), 1.07 (s, 3H).
Example 9: (5)-3-aimno-/V-(l-hydroxy-3-(lJ/-imidazol-4-yI)propan-2-yl)-3,3- 
dimethylpropanamide ( FLM-02 OLO)
15 (53-methvl-2-(3-((/ert-butoxvcarbonvl)aruino)-3 J-dimethylpropanamido)-3-(177-
imidazol-4-yl)propanoate (procedure 1 )
1H NMR (300 MHz, CDCl3) δ 7.60 (s, 1H), 7.15 (d, J= 7.3 Hz, 1H), 6.83 (s, 1H), 
5.39 (s, 1H), 4.88 - 4.74 (m, 1H), 3.70 (s, 3H), 3.12 (d, J= 5.3 Hz, 2H), 2.56 (q, J= 13.7 
Hz, 2H), 1.41 (s, 9H), 1.38 (s, 3H), 1.37 (s, 3H).
20 (S)-fert-butyl(3-(( 1 -hydroxv-3-(17J-imidazol-4-yl)propan-2-vDaminoV3.3-
dimethyl-3-oxopropyl) carbamate (procedure 2. yield 81%).
1H NMR (300 MHz, CD3OD) δ 7.64 (s, 1H), 6.89 (s, 1H), 4.20 - 4.05 (m, 1H), 
3.53 (d, J= 5.2 Hz, 2H), 2.89 (dd, J= 14.9, 6.0 Hz, 1H), 2.74 (dd, J= 14.9, 8.2 Hz, 1H), 
2.45 (s, 2H), 1.42 (s, 9H), 1.29 (s, 3H), 1.26 (s, 3H).
25 (5)-3-amino-iV-( 1 -hydroxy-3-( 177-imidazol-4-yl)propan-2-yl)-3,3 -
dimethvlpropanamide (procedure 3, yield 90%).
1H NMR (300 MHz, CD3OD) δ 7.56 (s, 1H), 6.85 (s, 1H), 4.22 - 4.10 (m, 1H), 
3.61 - 3.48 (m, 2H), 2.88 (dd, J= 14.9, 5.7 Hz, 1H), 2.73 (dd, J= 14.9, 8.5 Hz, 2H), 2.22
18
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(s, 2H), 1.11 (s, 3H), 1.09 (s, 3H).
Example 10: (5)-3-ammo-2,2-difluoro-iV-(l-liydroxy-3-(li/-imidazol-4-
yl)propan-2-yl)propanamide (FLM-07-OLO)
The compound was prepared with a slightly different procedure by coupling 
5 between (S)-2-amino-3-(17/-imidazol-4-yl)propyl acetate and Fmoc-3-amino-2,2- 
difluoro-propionyl chloride.
The resulting compound (S)-2-(3-(((9Tr-fluoren-9-yl)methoxy)carbonylamino)- 
2,2-difluoropropanamido)-3-(177-imidazol-4-yl)propyl acetate was then deprotected to 
give the final aminoalcohol.
10 (■Sf)-2-f3-f((9ij-fluoren-9-vl)methoxv)carbonvlamino)-2.2-difluoropropanamidoV
3-Π /7-imidazol-4-vl)propyl acetate (Yield 70%).
1H NMR (300 MHz, CD3OD) δ 7.79 (d, J= 7.5 Hz, 2H), 7.64 (d, J= 7.5 Hz, 2H), 
7.58 (s, 1H), 7.38 (t, J= 7.3 Hz, 2H), 7.30 (t, J= 7.3 Hz, 2H), 6.87 (s, 1H), 4.44 - 4.32 
(m, 3H), 4.25 - 4.15 (m, 2H), 4.07 - 3.99 (m, 1H), 3.70 (t, J= 14.5 Hz, 2H), 2.93 - 2.77 
15 (m, 2H), 2.01 (s, 3H).
(5r)-3-amino-2.2-difluoro-jV-( 1 -hydroxv-3-f 1 /jr-imidazol-4-yl)propan-2-
vl)propanamide
(Yield 99%)
1H NMR (300 MHz, D2O) δ 7.73 (s, 1H), 6.97 (s, 1H), 4.38 - 4.22 (m, 1H), 3.79 
20 (dd, J= 11.7, 4.6 Hz, 1H), 3.66 (dd, J= 11.8, 7.4 Hz, 1H), 3.05 (t, J= 15.3 Hz, 2H), 2.95 
(dd, J= 14.9, 4.9 Hz, 1H), 2.77 (dd, J= 14.9,10.0 Hz, 1H).
Example 11: N-(2-amino-2-methyIpropanoyI)-L-histidine (FLM-05-ACI) 
(procedure 4. Yield 80%)
1HNMR (300 MHz, D2O) δ 7.75 (s, 1H), 6.93 (s, 1H), 4.45 (dd, J= 9.0,4.9 Hz, 1H), 
25 3.16 (dd, J= 15.0,4.8 Hz, 1H), 2.98 (dd, J= 15.0,9.0 Hz, 1H), 1.49 (s, 3H), 1.37 (s, 3H).
Example 12: N-(3-amino-2,2-dimethylpropanoyI)-L-Mstidme(FLM-04-ACI) 
(procedure 4. Yield 65%)
1H NMR (300 MHz, D2O) 87.73 (s, 1H), 6.95 (s, 1H), 4.46 (dd, J= 8.7, 4.8 Hz,
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Example 13: N-(l-aminometliyI)-l-cycIopropylcarboiiyi)-L-histidme.
(FLM-09-ACI)
(procedure 4. Yield 99%)
1H NMR (300 MHz, D2O) δ 7.64 (s, 1H), 6.89 (s, 1H), 4.42 (dd, J = 8.7, 4.8 Hz, 
1H), 3.16-2.82 (m, 4H), 1.22-1.07 (m, 1H), 1.05-0.83 (m, 3H).
Example 14: N-(l-aminomethyl)-l-cydobutylcarbonyI)-L-faistidine
(FLM-10-ACI)
(procedure 4. Yield 93%)
1H NMR (300 MHz, d2o) 5 7.77 (s, 1H), 7.01 (s, 1H), 4.52 (dd, J = 9.1, 4.7 Hz, 
1H), 3.42 - 3.29 (m, 2H), 3.24 (dd, J= 15.0, 4.6 Hz, 1H), 3.04 (dd, J= 15.0, 9.1 Hz, 1H), 
2.43-2.19 (m,2H), 2.18-1.93 (m, 3H), 1.92-1.78 (m, 1H).
Example. 15: N-(l-aminomethyl)-l-cyclopentylcarbonyI)-L-histidine
(FLM-Il-ACI)
(procedure 4. Yield 99%)
1H NMR (300 MHz, CD3OD) S 7.56 (s, 1H), 6.83 (s, 1H), 4.45 (dd, J= 8.1, 4.3 
Hz, 1H), 3.23 (dd, J= 14.9, 4.3 Hz, 1H), 3.10 - 2.93 (m, 3H), 2.18 - 1.95 (m, 2H), 
1.75-1.47 (m,6H).
Example 16: N-(l-aminomethyl)-l-cyclohexylcarbonyl)-L-histidme (FLM-14-
ACI)
(procedure 4. Yield 100%)
1H NMR (300 MHz, CD3OD) δ 7.56 (s, 1H), 6.84 (s, 1H), 4.48 (dd, J= 8.6, 4.3 
Hz, 1H), 3.26 (dd, J= 15.0, 4.5 Hz, 1H), 3.05 (dd, J= 15.0, 8.7 Hz, 1H), 2.98 - 2.79 (m, 
2H), 2.10 (d, J= 12.2 Hz, 2H), 1.64 - 1.45 (m, 3H), 1.45-1.12 (m, 5H).
Example 17: N-(4-amino-2,2-dimethylbutanoyI)-L-histidme(FLM-13-ACI) 
(procedure 4. Yield 100%)
1H NMR (300 MHz, D2O) δ 7.59 (s, 1H), 6.86 (s, 1H), 4.40 (dd, J= 9.1, 4.7 Hz, 
1H), 3.08 (dd, J= 14.9, 4.7 Hz, 1H), 2.90 (dd, J= 14.9, 9.1 Hz, 1H), 2.58 - 2.38 (m, 2H),
20
1H), 3.18 (dd, J= 15.0, 4.9 Hz, 1H), 3.11-2.95 (m, 3H), 1.29 (s, 3H), 1.16 (s, 3H).
WO 2019/130164 PCT/IB2018/060332
21
1.67 - 1.56 (m, 2H), 1.07 (s, 3H), 1.04 (s, 3H).
Example 18: N-(3-amino-3,3-dimethylpropamoyl)-L-histidme(FLM-02-ACI)
(procedure 4. Yield 100%)
1H NMR (300 MHz, D2O) <5 7.65 (s, 1H), 6.93 (s, 1H), 4.49 (dd, J- 9.8, 4.4 Hz, 
5 1H), 3.15 (dd, J= 15.0, 4.4 Hz, 1H), 2.92 (dd, J= 14.9, 9.9 Hz, 1H), 2.37 (s,J= 14.1 Hz,
2H), 1.13 (s, 3H), 1.08 (s, 3H).
Example 19: N-(3-amino-2,2-dimeihylpropanoyl)-L-Msiidine (FLM-12-ACI)
(procedure 4. Yield 90%)
1H NMR (300 MHz, D2O) δ 7.69 (s, 1H), 6.86 (s, 1H), 4.53 (dd, J= 10.0, 4.8 Hz, 
10 1H), 3.70 (s, 3H), 3.26 (dd, J= 15.5, 4.7 Hz, 1H), 3.13-2.96 (m, 3H), 1.32 (s, 3H), 1.17
(s, 3H).
Example 20: N-(3-ammo-2,2-difIuoropropanoyl)-L-histidine(FLM-07-ACI)
(procedure 4. Yield 95%)
1H NMR (300 MHz, D2O) δ 8.16 (s, 1H), 7.11 (s, 1H), 4.53 (dd, J= 9.1, 4.8 Hz, 
15 1H), 3.34 - 3.23 (m, 3H), 3.07 (dd, J= 15.2, 9.2 Hz, 1H).
1H NMR (300 MHz, D2O) δ 8.16 (s, 1H), 7.11 (s, 1H), 4.53 (dd, J= 9.1, 4.8 Hz, 
1H), 3.34 - 3.23 (m, 3H), 3.07 (dd, J= 15.2, 9.2 Hz, 1H).
Pharmacological Tests
The carbonyl-quenching activity of a selected series of compounds according to 
20 the invention has been demonstrated in vitro by incubating HNE (50 μΜ) with the 
molecule under study (1 mM), in phosphate buffer (10 mM), pH 7.4, at 37°C. The activity 
was evaluated one and three hours after incubation, determining the residual HNE content 
by reverse-phase chromatography as previously described by Aldini G. et al. [Biochem 
Biophys Res Commun. 2002 Nov 15;298(5):699-706]. The carbonyl-quenching activity is 
25 evaluated on the basis of tire percentage of HNE reacted, compared with the HNE content 
in the absence of the molecule to be tested.
The stability in human serum of the compound most active in the preceding test 
was also evaluated by incubation at 37°C and subsequent sampling at O min, 15 min, 30
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min, 1 h and 2 h. The samples taken from each matrix, suitably treated, were analysed by 
HPLC-MS, obtaining recovery after 1 h and 2 h.
The results are summarised in the tables below:
Table I
22
COMPOUND ACTIVITY (CARNOSINE 
UNIT)
HNE CONSUMPTION (%)
Ih 3 h Ih 3 h
FLM-02-ACI 0.02 0.14 0.40±1.73 6.05il.66
FLM-04-ACI 1.76 1.51 30.06±4.68 64.44i4.37
FLM-05-ACI 0.33 0.37 5.58±7.50 15.84il0.65
FLM-07-ACI 0.46 0.69 7.88±5.41 29.42i6.42
FLM-09-ACI 0.81 0.89 13.70±0.83 36.11i2.87
FLM-IO-ACI 1.06 1.11 17.89±1.97 45.04i2.94
FLM-Il-ACI 1.41 1.31 23.82±1.55 53.54il.10
FLM-12-ACI 1.58 1.20 27.07i9.77 51.35i9.22
FLM-13-ACI 0.69 0.48 11.77±6.79 20.43i7.94
FLM-14-ACI 1.71 1.36 29.10±2.97 58.03i2.37
FLM-02-OLO 0.25 0.24 4.09±2.61 10.50i2.24
FLM-04-OLO 3.13 2.00 52.14±5.56 86.47i2.73
FLM-05-OLO 0.38 0.45 6.40±1.72 19.44i2.36
FLM-07-OLO 1 0.82 17.07±1.76 34.93i0.58
FLM-09-OLO 1.55 1.45 26.21±1.04 59.09il.49
FLM-IO-OLO 2.82 2.08 47.68±3.02 84.63i2.70
FLM-Il-OLO 2.82 2.06 47.56i0.69 83.90i0.33
FLM-12-OLO 2.98 1.64 50.77i3.84 70.08i2.98
FLM-13-OLO 0.62 0.54 10.54il0.04 23.05il2.28
FLM-14-OLO 2.84 1.96 48.36i6.22 83.50i5.85
BLANK 0.12 0.04 2.00i0.66 1.88i0.69
CARNOSINE 1.00 1.00 17.05il.24 42.66i0.89
Table II
COMPOUND Stability in plasma (% residual amount)
Ih 2h
FLM-04-OL 101.78il6.20 100.34i9.46
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CLAIMS
1. Compounds of general formula I
R
NH
I
wherein:
10
15
Rl is a 5-6-membered heterocyclic ring optionally fused to a benzene ring, 
containing one to three nitrogen atoms optionally bearing C1-C3 alkyl substituents;
R2 is selected from:
- a CBh O-R group wherein R is hydrogen, a straight or branched C1-C10 alkyl 
group or a C3-C8 cycloalkyl group, a straight or branched Ci-Cs alkylcarbonyl group, a 
C3-C8 cycloalkylcarbonyl group; or R is an Ar(CH2)PC(=0)- group wherein Ar is aryl 
selected from phenyl and naphthyl optionally substituted with one or two groups selected 
from the group consisting of methyl, methoxy or ethyl and p is zero or an integer ranging 
from 1 to 3;
- a COORe group wherein Rs is hydrogen, a straight or branched C1-C10 alkyl 
group or a C3-C8 cycloalkyl group;
R3 is a group of general formula II
D
(CH2)n (CH2)q
Π
wherein
n and q, independently one from the other, are zero or are an integer ranging from
25 1 to 4;
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Re and R7, which can be the same or different, are:
- hydrogen;
- a straight or branched C1-C20 alkylcarbonyl or C3-C7 cycloalkylcarbonyl group 
optionally containing one or more double bonds, or an Ar(CH2)PC(=0)- group wherein
5 Ar and p are as defined above;
- a straight or branched C1-C10 alkoxycarbonyl or C3-C7 cycloalkoxycarbonyl 
group optionally containing one or more double bonds or an Ar0(CH2)nC(=0)- group 
wherein Ar and p are as defined above;
- one of R6 and R7 is an amino group and the other is hydrogen;
10 - one or R6 and R7 is hydrogen and the other is a group of formula III
24
M
H
III
15
20
wherein M is nitrogen, oxygen or sulphur and A is hydrogen or an amino group, 
and the free valence of the carbon atom forms a bond with the nitrogen atom of the group 
of formula II;
R4 and Rs, which can be the same or different, are: ·
- a straight or branched Ci-Cs alkyl group;
- a halogen;
- can be linked to form, together with the carbon atom to which they are bonded, a 
C3-C6 cycloaliphatic ring selected from cyclopropyl, cyclobutyl, cyclopentyl and 
cyclohexyl, forming an R3 group of general formula IV
R6 V—(CH2)Pi
R
V
N.
(CH2)n
O
(CH2)q
25 IV
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wherein
m has a value ranging from 1 to 4;
Re, R7, n and q have the meanings described above; 
wherein:
5 in general formula I, the wavy bond indicates that the carbon atom
substituted with NH and R2 can have the R or S configuration.
in general formulas II and IV the free valence at the carbon atom of the carbonyl 
group forms a bond with the nitrogen atom of formula I;
the optical isomers and diastereomers thereof, either in isolated or mixture form,
10 and the pharmacologically acceptable salts thereof.
2. Compovmds according to claim 1 wherein:
Ri is a heterocyclic ring selected from imidazole, pyrrole, pyrazole, triazole, 
indole, isoindole, indazole, benzimidazole and benzotriazole, preferably imidazole or 
imidazole substituted at the nitrogen atom at the 1- position or at the 3- position with 
15 methyl, ethyl or propyl;
R2 and R3 are as defined above.
3. Compovmds according to claim 1 or 2 wherein:
Ri is imidazole optionally substituted at the nitrogen atom at the 1- position or at
/
the 3- position with methyl, ethyl or propyl;
20 R2 is CH2-OH or a COORs group wherein Rs is selected from hydrogen, methyl
and ethyl;
R3 is a group of formula II wherein R4 and Rs are both methyl or halogen, R6 and 
R7 are both hydrogen or one of R6 and R7 is hydrogen and the other is a straight or 
branched C1-C10 alkoxycarbonyl or C3-C7 cyclic group, and n and q are as defined above.
25 4. Compounds according to claim 1 or 2 wherein:
Ri is imidazole optionally substituted at the nitrogen atom at the 1- position or at 
the 3- position with methyl, ethyl or propyl;
R2 is CH2-OH or a COORs group wherein Rs is selected from hydrogen, methyl
25
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and ethyl;
R3 is a group of formula IV wherein R4 and Rs are joined to form, together with 
the carbon atom to which they are bonded, a C3-C6 cycloaliphatic ring selected from 
cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; R6 and R7 are both hydrogen or one 
5 of Re and R7 is hydrogen and the other is a straight or branched C1-C10 alkoxycarbonyl or 
a C3-C7 cyclic group, and m, n and q are as defined above.
5. Compounds according to claim 1,2 or 3 wherein:
Ri is imidazole optionally substituted at the nitrogen atom at the 1- position or at 
the 3- position with methyl;
10 R2 is CH2-OH or a COORs group wherein Rs is hydrogen;
Rj is a group of formula II wherein R4 and Rs are both methyl or fluorine, R6 and 
R7 are both hydrogen, and n and q are as defined above.
6. Compounds according to claim 1, 2 or 4, wherein:
Ri is imidazole optionally substituted at the nitrogen atom at the 1- position or at 
15 the 3 - po sition with methyl;
R2 is CH2-OH or a COORs group wherein Rs is hydrogen;
R3 is a group of formula IV wherein R4 and Rs are joined to form, together with 
the carbon atom to which they are bonded, a C3-C6 cycloaliphatic ring selected from 
cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, Re e R7 are both hydrogen, and m, 
20 n and q are as defined above.
7. A compound according to claim 1 selected from:(S)-2-amino-N-(l-hydroxy-3- 
(1 H-imidazol-4-yl)propan-2-yl)-2-methylpropanamide;
(S)-3-amino-N-( 1-hydroxy-3-(1 H-imidazol-4-yl)propan-2-yl)-2,2- 
dimethylpropanamide;
25 ' (S)-4-amino-N-(l-hydroxy-3-(1 H-imidazol-4-yl)propan-2-yl)-2,2-
dimethylbutanamide;
(S)-I -(aminomethyl)-N-(1 -hydroxy-3 -(1 H-imidazol-4-y l)propan-2- 
yl)cyclopropanecarboxamide;
26
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(S)-I -(aminomethyl)-N-( 1 -hydroxy-3 -(1 H-imidazol-4-yl)propan-2- 
yl)cyclobutanecarboxamide;
(S)-I -(aminomethyl)-N-(l -hydroxy-3-(lH-imidazol-4-yl)propan-2- 
yl)cyclopentanecarboxamide;
(S)-1 -(aminomethyl)-N-( 1 -hydroxy-3-(1 H-imidazol-4-yl)propan-2- 
yl)cyclohexanecarboxamide;
(S)-3 -amino-N-(1 -hydroxy-3 -(1 -methyl-1 H-imidazol-5 -yl)propan~2-yl)-2,2- 
dimethylpropanamide;
(S)-3 -amino-N-(1 -hydroxy-3 -(1 H-imidazol-4-yl)propan-2-yl)-3,3 - 
dimethylpropanamide;
(S)-3-amino-2,2-difluoro-N-(l-hydroxy-3-(lH-imidazol-4-yl)propan-2-
yl)propanamide;
N-(2-amino-2-methylpropanoyl)-L-histidine;
N-(3-amino-2,2-dimethylpropanoyl)-L-histidine
N-( 1 -aminomethyl)-1 -cyclopropylcarbonyl)-L-histidine;
N-(l -aminomethyl)-1 -cyclobutylcarbonyl)-L-histidine;
N-(l -aminomethyl)-1 -cyclopentylcarbonyl)-L-histidine 
N-( 1 -aminomethyl)-1 -cyclohexyl carbonyl)-L-histidine; 
N-(4-amino-2,2-dimethylbutanoyl)-L-histidine; 
N-(3-amino-3,3-dimethylpropanoyl)-L-histidine;
N-(3 -amino-2,2-dimethylpropanoyl)-L-histidine 
N-(3-amino-2,2-difluoropropanoyl)-L-histidine.
8. A compound according to claims 1 to 7 for use as a medicament.
9. A compound according to claim 8 for use in the treatment or prevention of 
neurodegenerative, chronic inflammatory and cardiovascular disorders and the 
complications of diabetes and cataract.
10. A pharmaceutical composition containing an effective amount of one or more of 
the compounds of claims 1-7 in combination with suitable excipients.
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